Compare Quest Diagnostics Inc (DGX) vs Mattel Inc (MAT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Mattel Inc — how do they compare? Quest Diagnostics Inc trades at $237.86 (market cap $26.21B), while Mattel Inc trades at $14.75 (market cap $4.30B). The key difference: Quest Diagnostics Inc is far larger — about 6.1× Mattel Inc's market cap, and Quest Diagnostics Inc pays a 1.45% dividend while Mattel Inc pays none. Which is the better fit depends on your goals.
| DGX | MAT | |
|---|---|---|
Market Cap | $26.21B | $4.30B |
Sector | Health | Consumer Cyclical |
52-Week High | $238.50 | $22.16 |
52-Week Low | $173.49 | $13.05 |
Enterprise Value | $31.97B | $6.52B |
Dividend Yield | 1.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.24, down 0.16% on the day, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $3.12 and raising its full-year outlook, driven by robust testing demand. Revenue grew to $11.04B in 2025, with net income of $992M, though margins face pressure from lower-margin deals and rising costs.
The outlook is positive due to raised guidance and AI integration enhancing efficiency, but risks include debt levels and margin compression. Analysts maintain a cautious buy stance with a $249.50 price target, indicating modest upside potential from current levels amid competitive and cost challenges.
Mattel (MAT) trades at $15.03, up 1.97% today, with a bullish technical signal from moving averages. The company reported mixed Q2 2026 results, with a 10% revenue beat but an earnings miss due to higher costs. Valuation ratios appear reasonable with a P/E of 11.22 and P/S of 0.84. Analyst consensus is a 'Hold' with a $14.00 price target, slightly below the current price. Recent news highlights growth from toy-based movies and adult collectors, though profit margins face pressure from advertising and SG&A expenses.
The outlook for Mattel is cautiously optimistic, driven by IP expansion and brand strength, but near-term risks include cost inflation and discretionary spending headwinds. Investment opportunity lies in execution of entertainment strategy, while key risks are margin compression and competitive pressures. The stock's current level near analyst targets suggests limited upside without improved earnings momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Mattel Inc
Mattel markets toy products that are sold to its wholesale customers and direct to retail consumers. The company offers products for children and families, including toys for infants and preschoolers, girls and boys, youth electronics, handheld and other games, puzzles, educational toys, media-driven products, and plush and fashion-related toys. Mattel's owned portfolio includes Barbie, Hot Wheels, Fisher-Price, Thomas & Friends, and American Girl. In addition, it currently manufactures toy products for its segments both internally and externally (through manufacturing partners). Just over half of its net sales are in North America, while the remainder stem from international markets.
Read more on MAT →
